Study results indicate that mutation strength may shape both tumor–immune system interactions and immunotherapy response.
Scientists have created a complete map showing how hundreds of possible mutations in a key cancer gene influence tumor growth. The study focused on CTNNB1, a gene that produces the protein β-catenin, ...
A new study published in Nature Genetics reveals that not all cancer-associated mutations in the same gene behave alike. Led ...
The onset and aggressiveness of cancer are related to the abnormal behavior of certain genes, known as oncogenes. The best-known of these alterations is mutation, but it is not the only one. Sometimes ...
February 4, 2026 Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST ...
Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of ...
Relay Therapeutics gets US FDA Breakthrough Therapy Designation for zovegalisib to treat advanced breast cancer: Cambridge, Massachusetts Thursday, February 5, 2026, 16:00 Hrs [IS ...
Scientists have created a complete map showing how hundreds of possible mutations in a key cancer gene influence tumour ...
The FDA granted Breakthrough Therapy status to zovegalisib plus Faslodex for patients with PIK3CA-mutated HR+/HER2- advanced breast cancer. The U.S. Food and Drug Administration (FDA) has granted ...
Scientists have created a complete map showing how hundreds of possible mutations in a key cancer gene influence tumour growth.
Researchers say the deep learning model may help to create leads for new cancer diagnostics, patient stratification, and future therapies.
February 4, 2026 Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results